Zolex Therapeutics
Treatment for Drug-resistant Bacterial Infections
Health Tech & Life Sciences
Non Active, Nov 2018
Company Overview
Snapshot
Founded in August 2016, Zolex Therapeutics operates with 1–10 employees. The company has raised $500,000 across one funding round. Zolex Therapeutics focuses on developing new classes of orally active, small-molecular-weight antibiotics.
Business overview
Zolex Therapeutics is a drug development company specializing in creating novel, orally active, small-molecular-weight antibiotics. The company's primary focus is on targeting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA) strains. Operating within the Health Tech & Life Sciences sector, Zolex Therapeutics addresses critical needs in pharmaceuticals and biopharmaceutical drug discovery.
Company Intelligence Q&A
- What is Zolex Therapeutics' primary focus?
- Zolex Therapeutics is focused on the development of new classes of orally active, small-molecular-weight antibiotics that target Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus strains.
- When was Zolex Therapeutics founded?
- Zolex Therapeutics was founded in August 2016.
- What is the employee count for Zolex Therapeutics?
- Zolex Therapeutics has 1–10 employees.
- What is the total capital raised by Zolex Therapeutics?
- Zolex Therapeutics has raised $500,000 in total funding.
- Where is Zolex Therapeutics located?
- Zolex Therapeutics is located at HaBarzel Street 27, Tel Aviv-Yafo, Israel, within the RadBioMed Accelerator at Ramat Hachayal.